Pre-Market Review: MannKind, Ariad Pharma, Galena Biopharma, and Novavax

   Pre-Market Review: MannKind, Ariad Pharma, Galena Biopharma, and Novavax

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

LONDON, June 28, 2013

LONDON, June 28, 2013 /PRNewswire/ --

On Thursday, June 27, 2013, shares in biotechnology companies ended mostly
higher, tracking gains in the broader market which rose for a third successive
trading session. The major movers in the sector included MannKind Corporation
(NASDAQ: MNKD), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Galena Biopharma
Inc. (NASDAQ: GALE), and Novavax Inc. (NASDAQ: NVAX).
initiated preliminary technical research on MNKD, ARIA, GALE, and NVAX. These
free reports are accessible by signing today at: 

Shares in MannKind Corporation rallied on Thursday, tracking gains in the
broader market. The company's shares ended the day 3.11% higher at $6.64 after
oscillating between $6.51 and $6.68. A total of 6.27 million shares were
traded which is below the daily average volume of 9.03 million. MannKind's
shares have gained 97.03% in the last three months, thus outperforming the S&P
500. Furthermore, the stock has a 52-week high of $8.06. The free technical
analysis on MNKD is available by signing up at:

Ariad Pharmaceuticals Inc.'s stock closed slightly lower on Thursday even as
the broader market posted gains. The company's shares fluctuated between
$17.19 and $18.05 before finishing the day 0.68% lower at $17.55. A total of
1.70 million shares were traded which is below the daily average volume of
2.87 million. Despite Thursday's pullback, the company's shares have gained
7.14% in the last three trading sessions. Register now to download free
research on ARIA at:

Shares in Galena Biopharma Inc. rallied on Thursday, extending their gains
from previous trading session. The company's shares closed 5.06% higher at
$2.18. A total of 1.51 million shares were traded which is below the daily
average volume of 1.93 million. The stock has gained 8.73% in the last two
trading sessions. The gains have pushed the stock above its 200-day moving
average. Nonetheless, the stock is still trading below its 50-day moving
average. A free report on GALE can be accessed by registering at:

Novavax Inc.'s stock moved higher on Thursday, reversing some of its recent
losses. The company's shares oscillated between $1.93 and $1.99 before closing
the day at $1.98, up 1.54%. A total of 590,817 shares were traded which is
below the daily average volume of 1.42 million. The company's shares are now
down 2.46% in the last three trading sessions. In the last three months, the
stock has dropped by 9.17%. Moreover, the stock has a 52-week high of $2.77.
Register with AAA Research Reports and download research on NVAX for free at:



1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE AAA Research Reports

Contact: Phone #: + 1 (646) 396-9126
Press spacebar to pause and continue. Press esc to stop.